Salivary and Serum B-cell Activating Factor (BAFF) Levels after Hydroxychloroquine Treatment in Primary Sjogren's Syndrome

Mumcu G., Bicakcigil M., Yilmaz N., Ozay H., Karacayli U., Cimilli H., ...Daha Fazla

ORAL HEALTH & PREVENTIVE DENTISTRY, cilt.11, sa.3, ss.229-234, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3290/j.ohpd.a30172
  • Dergi Adı: ORAL HEALTH & PREVENTIVE DENTISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.229-234
  • Anahtar Kelimeler: BAFF level, hydroxychloroquine, Sjogren's syndrome, QUALITY-OF-LIFE, DISEASE-ACTIVITY, FAMILY BAFF, LYMPHOCYTES, EXPRESSION, VALIDITY, GLANDS, BLOOD
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: Some evidence implicates a role of hydroxychloroquine (HQ) in the management of Sjogren's syndrome. This study evaluated the effect of HQ on saliva B-cell activating factor (BAFF) levels as well as health related quality of life (QoL) in patients with primary Sjogren's syndrome (pSS).